Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors
- 25 April 2013
- journal article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 71 (6), 1645-1655
- https://doi.org/10.1007/s00280-013-2165-2
Abstract
LY2334737 is an oral gemcitabine prodrug. This Phase I study assessed the safety and tolerability of LY2334737 in Japanese patients with solid tumors and evaluated pharmacokinetics (PK), pharmacodynamics, and antitumor activity. Patients with advanced/metastatic solid tumors received escalating doses of LY2334737 once daily for 14 days, followed by a 7-day drug-free period. Cycles were repeated until discontinuation criteria were met. Of 13 patients treated, 3 received 20 mg/day, 6 received 30 mg/day, 4 received 40 mg/day. On the 40 mg dose, 3 patients experienced dose-limiting toxicities (DLTs): hepatic toxicities (e.g., Grade [G]3/4 transaminase and G1–3 bilirubin elevation) and G4 thrombocytopenia; all 3 showed features of disseminated intravascular coagulation. One additional DLT occurred on the 30 mg dose (G3 transaminase elevation). Exploratory pharmacogenetic analyses identified a genetic variation in the CES2 gene potentially associated with these DLTs. PK data showed no clear relationship between the AUC of gemcitabine and its incorporation into leukocyte DNA; 2 of the 3 DLT patients had high incorporation. Two patients (30 mg/day) achieved stable disease with progression-free survival lasting 135 and 155 days. LY2334737 was tolerated by Japanese patients up to 30 mg/day. The toxicities observed at the 40 mg dose may require the development of alternative dosing schedules.Keywords
This publication has 23 references indexed in Scilit:
- Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor XenograftsMolecular Cancer Therapeutics, 2013
- Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical ModificationsMolecular Pharmaceutics, 2012
- Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of GemcitabineJournal of Medicinal Chemistry, 2009
- Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic StudyClinical Cancer Research, 2008
- Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trialThe Esophagus, 2006
- A Pilot Study of Individualized Maximum Repeatable Dose (iMRD), a New Dose Finding System, of Weekly Gemcitabine for Patients With Metastatic Pancreas CancerPancreas, 2005
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous LeukemiaJournal of Clinical Oncology, 2002
- Phase II Clinical Investigation of Gemcitabine in Advanced Soft Tissue Sarcomas and Window Evaluation of Dose Rate on Gemcitabine Triphosphate AccumulationJournal of Clinical Oncology, 2001
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991